9017 related articles for article (PubMed ID: 18773755)
1. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
[TBL] [Abstract][Full Text] [Related]
4. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
[TBL] [Abstract][Full Text] [Related]
5. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
6. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
Padwal RS; Majumdar SR
Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacotherapy in the treatment of obesity].
Hamann A
MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
[TBL] [Abstract][Full Text] [Related]
8. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
[TBL] [Abstract][Full Text] [Related]
9. Rimonabant for the treatment of overweight and obese people.
Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
[TBL] [Abstract][Full Text] [Related]
10. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
Ara R; Blake L; Gray L; Hernández M; Crowther M; Dunkley A; Warren F; Jackson R; Rees A; Stevenson M; Abrams K; Cooper N; Davies M; Khunti K; Sutton A
Health Technol Assess; 2012; 16(5):iii-xiv, 1-195. PubMed ID: 22340890
[TBL] [Abstract][Full Text] [Related]
11. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
12. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
13. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
14. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen AJ; Ernest P
Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
[TBL] [Abstract][Full Text] [Related]
15. Modern medical management of obesity: the role of pharmaceutical intervention.
Aronne LJ
J Am Diet Assoc; 1998 Oct; 98(10 Suppl 2):S23-6. PubMed ID: 9787732
[TBL] [Abstract][Full Text] [Related]
16. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
[TBL] [Abstract][Full Text] [Related]
18. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
[TBL] [Abstract][Full Text] [Related]
19. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of weight-reducing drugs in hypertensive patients.
Siebenhofer A; Horvath K; Jeitler K; Berghold A; Stich AK; Matyas E; Pignitter N; Siering U
Cochrane Database Syst Rev; 2009 Jul; (3):CD007654. PubMed ID: 19588440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
